Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Osteolysis 1Multiple Myeloma 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

Denosumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypercalcemia × ARQ 197 × Plasma cell × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡